(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
We at the Division of Allergy and Immunology at Cincinnati
Children’s are devoted to providing the best care for our patients. Our
dedicated clinical staff partner with families to improve the health and
quality of life of our patients. Our
involvement in human research studies, also known as clinical trials, helps us to
determine what treatments and strategies work best for our patients. Our division’s clinical trials team is dedicated to bringing cutting-edge therapies to our child and adult patients.
Have you been searching for the latest research studies for Eosinophilic Gastrointestinal Disease (EGID)?
Join the Rare Diseases Clinical Research Network (RDCRN) Contact Registry today!
If so, you are invited to sign up for the Rare Diseases Clinical Research Network (RDCRN) Contact Registry.
The RDCRN Contact Registry is a way that patients with rare disorders, like EGID, can receive information about new research studies, eligibility for participation in clinical studies/trials, and updates on results of such studies.
Patients who participate in research make it possible for researchers to find new treatments, create new studies, and work for the improvement of all EGID patients. It can also help connect you with Patient Advocacy Groups (PAGs).
Find out more about the RDCRN Contact Registry, or join the registry.
The purpose of this observational research study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EG, and EC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.
Children and adults ages 3-65 years that have been diagnosed with EoE, EG, or EC.
General CEGIR OMEGA Description (PDF)Adult (18-65 years) CEGIR OMEGA (PDF)Pediatric (3-17 years) CEGIR OMEGA (PDF)
Jonathan Kuhl, BS, 513-803-3078, Jonathan.firstname.lastname@example.org
The purpose of this research study is to test the effects of two elimination dietary therapies—the 1 Food Elimination Diet (1FED) (Milk) vs. the 6 Food Elimination Diet (6FED) (Milk, Egg, Wheat, Soy, Peanut/tree nuts, and fish/shellfish) in patients diagnosed with EoE. This study also aims to test participant’s response to swallowed glucocorticoids (Flovent) in participants who do not respond to the 6-Food elimination diet. Flovent is a topical steroid (taken using an inhaler) approved by the FDA to treat asthma, but that is also used for patients with EoE.
Adults ages 18-60 years that have been diagnosed with EoE.
SOFEED Study (PDF)
CCHMC IRB # 2012-0106: V2
The Cincinnati Center for Eosinophilic Disorders is conducting a research study to test whether losartan decreases the number of eosinophils in the esophagus of participants with active EoE, with or without a connective tissue disorder (CTD).
We are enrolling participants for a 4 month open label drug trial. This involves several visits to Cincinnati Children’s, blood draws, biopsies taken from EGD, and having vitals taken.
Participation will take place at Cincinnati Children’s, over the phone and through the mail.
People with active EoE with or without a CTD
If you have questions or are interested in participating, contact Jonathan Kuhl at Jonathan.Kuhl@cchmc.org or 513-803-3078.
Eosinophilic Esophagitis Medication Study (PDF)
CCHMC IRB #2014-2318:V1
We want to learn if a drug, called omalizumab, will help children and adults with multiple food allergies be able to safely ingest the foods they are allergic to.
Omalizumab is investigational because the U.S. Food and Drug Administration (FDA) has not yet approved it for the treatment of food allergies in children and adults. It is approved for the treatment of asthma in children and adults,
12 and above.
Children, teens and adults, 4 to 55 years old, who have 2 or more food allergies, may be eligible to participate. Food allergies include: peanut, milk, egg, wheat, soy, sesame seed, fish, shellfish and/or certain tree nuts (almond, cashew, walnut, hazelnut, pecan).
Anyone with an oat allergy, moderate or severe persistent asthma, and/or eosinophilic disorders will not be able to participate.
Participants may receive from $20 to $40 per visit for their time and travel.
Lisa Thornbury Clark at 513-803-3663 or email@example.com.
Cincinnati Children's Multiple Food Allergies Study (ages 4-55) (PDF)
CCHMC IRB #2013-6150:V1
We want to find out if there is a way to help lower the risk of severe allergic reactions for children and adults with an allergy to peanuts.
Children, teens and adults, 4 to 26 years old, who have a documented history of peanut allergy may be eligible to participate.
Participants may receive $50 per completed study visit for their time and travel.
For more information, please contact firstname.lastname@example.org or 513-803-FOOD.
Cincinnati Children's Peanut Allergy Study (ages 4-26) (PDF)
CCHMC IRB #2012-1498:V1
6 to 55 Year Olds for Peanut Allergy Medication Research Study
This is a research study to evaluate the safety and effectiveness of the investigational medication Viaskin® Peanut for treating peanut allergy in children and adults.
To date, there is no specific approved treatment for peanut allergy, which can be quite severe and life-threatening. The only management recommended for patients allergic to peanuts is strict avoidance. However, peanut is a very common ingredient in many foods and is not always reported in all ingredients.
Children and adults 6 to 55 years old who have a well-documented history of peanut allergy and are currently following a strict peanut-free diet may be eligible to participate.
Participants may receive up to $480 for travel related expenses for completing all 12 study visits ($40 per completed study visit).
For more information, please email email@example.com or call 1-513-803-FOOD
Cincinnati Children's Peanut Allergy Study (ages 6-55) (PDF)
CCHMC IRB #2012-2698:V1
This is a research study to learn more about the safety and effectiveness of a drug called mepolizumab in treating asthma. Researchers want to know if mepolizumab can lower the amount of oral steroids a person needs to take to treat their asthma.
Children, teens and adults 12 years old and older who:
Participants may be paid up to $465 for completing all study visits.
For more information, please contact Erin Brockman at firstname.lastname@example.org or 513-636-7897.
Cincinnati Children's Asthma Medication Research Study (PDF)
CCHMC IRB #2012-1422:V1
The purpose of this research study is to evaluate the safety and effectiveness of an investigational medication. The study will examine whether this medication is beneficial in improving lung function in patients with moderate to severe asthma and compare its effectiveness among certain types of patients.
Adults 18 to 75 years old who:
Participants may receive compensation for their travel and time.
For more information, please email email@example.com or call 1-513-636-AZMA
Cincinnati Children's Moderate to Severe Asthma Study
CCHMC IRB #2012-2702:V1
This is a research study to learn more about the safety and effectiveness of a new drug, called mepolizumab, in treating asthma.
Researchers also want to know how the body reacts to the drug and if there is a change in the number of asthma attacks a person has while taking mepolizumab.
Children, teens and adults 12 years old and older who been diagnosed with asthma AND:
Participants may receive compensation for their travel and time.
For more information, contact Erin Brockman at firstname.lastname@example.org or 513-636-7897.
Cincinnati Children's Severe Asthma Medication Research Study (PDF)
Our clinician researchers, such as Amal H. Assa'ad, MD, are devoted to providing the best in pediatric and adult care.
Our clinical trials are not only for children. See the Ongoing Clinical Trials descriptions (left) for specifics of who are eligible to participate.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center